Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT01214239

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01214239
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
China, Malaysia, Philippines (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01214239. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-07-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01214239
Content hash
cbb29eeae4f67bbf135b79b6fd1f248d439d48f8b444a7acf41a43ca70dc0d4c